Maxime Dumais holds a B.Sc. degree from the Université de Montréal in Microbiology and Immunology. The positions he held in his seven years working for the Quebec Breast Cancer Foundation included Director, Research and Health Promotion and Vice-President, Programs and Investments. Prior to that, Maxime was Program Manager at Génome Québec.
With over 15 years experience in research, Charles Meunier worked in academia, in translational research as well as in the biopharmaceutical industry. Before joining Oncopole, he was project manager at the Genome center with Jiannis Ragoussis. Charles obtained his PhD in cancer genetics and completed his post-doctoral work first at Hubrecht Institute (Netherlands) and then, at the Ottawa Hospital Research Institute (OHRI), working in stem cell research.
Serge Marchand, PhD
Serge Marchand, Ph.D., is the Scientific Director of the FRQS. Prior to his appointment (August 2017), he was Professor at the Faculty of Medicine at the Université de Sherbrooke, and director of pain research labs at the Sherbrooke University Hospital Research Center. He completed his PhD in Neuroscience at Université de Montréal in 1992 and his post-doctoral training at the University of California in 1994. He held the Joint Chair in Physiopathology of Pain UQAT-Université de Sherbrooke (2002-2010), and was the Scientific Director of the CHUS Research Center (2008-2013). He has authored several articles, book chapters and books on the neurophysiology of pain, and served on numerous national and international evaluation committees. His research focuses on the neurophysiological mechanisms responsible for the development and persistence of chronic pain.
Anne-Marie Larose, PhD, MBA
Anne-Marie Larose is the President and CEO of Aligo Innovation, whose creation she oversaw in 2014. Along with a Doctoral degree in molecular and cellular biology (Université de Laval) as well as an MBA in bio-industries (UQAM), she brings more than twenty years of varied experience in business, research and innovation (in the public and private sectors) and has extensive knowledge of the mechanisms and issues related to intellectual property enhancement and commercialization. She has held various positions throughout her career, among them commercial attaché to the Consulate of Great Britain in life sciences and biotechnologies, and has successfully carried out several cooperative research agreements within the industry.
Merck Canada Inc.
Jennifer Chan is Vice President, Policy & External Affairs, at Merck and is responsible for the company’s team of government relations and public affairs specialists. Upon receiving a Master’s degree in pharmacology and therapeutics from McGill University, she began her career in academic research, before joining Schering-Plough in 1993. She has since worked in various areas of this company, which merged with Merck in 2009. Member of several Boards of Directors, among which the Institute of Health Economics in Alberta and the Quebec Consortium for Drug Discovery, she is co-chair of the Canadian Biosimilars Forum and serves as a Merck for Mothers ambassador in Canada.
Anne-Marie Mes-Masson, PhD
Research Center of CHUM (University of Montreal)
Morag Park, PhD
Goodman Cancer Research Center (McGill University)
Michel Bouvier, PhD
Institute for Research in Immunology and Cancer
Co-leader (Entrepreneurship and promotion of innovation)
Michèle de Guise, MD, MM
Institut national d'excellence en santé et en services sociaux (INESSS)
Co-leader (Clinical relevance)
Bernard Lespérance, MD
Research Center of HSCM (University of Montreal)
Co-leader (Clinical relevance)